The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Up 86.8% in December

The Oncology Institute, Inc. (NASDAQ:TOI) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 324,100 shares, a growth of 86.8% from the December 15th total of 173,500 shares. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.9% of the company’s stock are short sold.

Insider Activity

In other Oncology Institute news, Director Brad Hively purchased 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were purchased at an average cost of $0.17 per share, with a total value of $42,500.00. Following the completion of the transaction, the director now owns 616,753 shares of the company’s stock, valued at approximately $104,848.01. This represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of Oncology Institute

An institutional investor recently raised its position in Oncology Institute stock. HighTower Advisors LLC boosted its stake in The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 81,362 shares of the company’s stock after buying an additional 53,382 shares during the quarter. HighTower Advisors LLC owned approximately 0.11% of Oncology Institute worth $27,000 at the end of the most recent quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Stock Up 8.1 %

NASDAQ TOI traded up $0.03 during trading on Wednesday, reaching $0.40. 2,596,948 shares of the company’s stock were exchanged, compared to its average volume of 711,372. The firm has a market capitalization of $30.22 million, a PE ratio of -0.51 and a beta of 0.13. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $2.45. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The company’s fifty day simple moving average is $0.23 and its 200-day simple moving average is $0.33.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.